Procarbazine
Matulane (procarbazine) is a small molecule pharmaceutical. Procarbazine was first approved as Matulane on 1982-01-01. It is used to treat brain neoplasms, hodgkin disease, lung neoplasms, melanoma, and multiple myeloma amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Matulane
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Procarbazine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MATULANE | Leadiant Biosciences | N-016785 RX | 1982-01-01 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| matulane | New Drug Application | 2024-09-16 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0182 | Procarbazine hydrochloride, oral, 50 mg |
Clinical
Clinical Trials
85 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 6 | 35 | 12 | — | 5 | 55 |
| Hodgkin disease | D006689 | — | C81 | 1 | 19 | 12 | — | 2 | 33 |
| Central nervous system neoplasms | D016543 | — | — | 5 | 7 | 9 | — | — | 18 |
| Nervous system neoplasms | D009423 | — | — | 4 | 7 | 9 | — | — | 17 |
| Glioma | D005910 | EFO_0000520 | — | — | 1 | 4 | — | 1 | 6 |
| Oligodendroglioma | D009837 | EFO_0000631 | — | — | 1 | 5 | — | — | 6 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | 3 | 2 | — | — | 5 |
| Astrocytoma | D001254 | EFO_0000271 | — | — | 2 | 2 | — | — | 4 |
| Recurrence | D012008 | — | — | — | 1 | 1 | — | 1 | 3 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | 1 | — | — | 2 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 5 | — | — | — | 5 |
| Neurotoxicity syndromes | D020258 | — | G92 | 1 | 2 | — | — | — | 3 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 1 | 2 | — | — | — | 2 |
| Primitive neuroectodermal tumors | D018242 | — | — | — | 1 | — | — | — | 1 |
| Neuroectodermal tumors | D017599 | — | — | — | 1 | — | — | — | 1 |
| Follicular lymphoma | D008224 | — | C82 | — | 1 | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 1 | — | — | — | 1 |
| Radiation effects | D011830 | — | — | — | 1 | — | — | — | 1 |
| Mantle-cell lymphoma | D020522 | — | — | — | 1 | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ataxia | D001259 | — | R27.0 | — | — | — | — | 1 | 1 |
| Ataxia telangiectasia | D001260 | Orphanet_100 | G11.3 | — | — | — | — | 1 | 1 |
| Telangiectasis | D013684 | — | — | — | — | — | — | 1 | 1 |
| Cerebellar ataxia | D002524 | HP_0001251 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Procarbazine |
| INN | procarbazine |
| Description | Procarbazine is a benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands. It has a role as an antineoplastic agent. It is a member of hydrazines and a member of benzamides. It is a conjugate base of a procarbazine(1+). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNNCc1ccc(C(=O)NC(C)C)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 671-16-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1321 |
| ChEBI ID | 71417 |
| PubChem CID | 4915 |
| DrugBank | DB01168 |
| UNII ID | 35S93Y190K (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Procarbazine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,603 documents
View more details
Safety
Black-box Warning
Black-box warning for: Matulane
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,807 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use